Remigiusz Zięba, Katarzyna Kocon

Rymonabant - pierwszy selektywny antagonista receptora kannabinoidowego CB1 stosowany w leczeniu otyłości

Rimonabant - the first selective cannabinoid-1 receptor antagonist used for obesity treatment. Rimonabant (Acomplia) - a selective cannabinoid-1 receptor antagonist - is a novel drug used for long-term treatment of obesity. Clinical studies have shown that rimonabant 20 mg once daily during 1 year significantly reduces body weight and waist circumference in obese patients. Rimonabant improves lipid and glycemic profiles. It is used as an adjunct to diet and exercise for the treatment of obese patients or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaemia. The most common adverse events leading to discontinuation from the clinical studies were psychiatric disorders, mainly depression and anxiety.